☆ 4.8 Article

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

LANCET (2021)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started